Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 36Pemetrexed 28Bevacizumab 26Cisplatin 24Paclitaxel 22Gemcitabine 20Radiotherapy 18Docetaxel 18Erlotinib Hydrochloride 15Gefitinib 11pembrolizumab 6Cetuximab 6capmatinib 5Surgical Procedures, Operative 5Radiosurgery 5aflutinib 4Vinorelbine 4Taxes 4Platinum 4Nivolumab 4Metformin 4pegfilgrastim 3durvalumab 3ceritinib 3apatinib 3Sorafenib 3Radiation 3Neoadjuvant Therapy 3Magnetic Resonance Spectroscopy 3tislelizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adenocarcinoma of Lung × Genetic Linkage × Clear all
NCT01557959 2018-06-29

Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Wake Forest University Health Sciences

Phase 2 Completed
45 enrolled 9 charts
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡